Comparative measurement of anti-factor VIII antibody by Bethesda assay and ELISA reveals restricted isotype profile and epitope specificity

Acta Haematologica

Volumn 114, Issue 2, 2005, Pages 84-90

  Towfighi, Farzaneh ^a,b   Gharagozlou, Soheila ^a   Sharifian, Ramazan Ali ^a   Kazemnejad, Anoushirvan ^b   Esmailzadeh, Khadijeh ^a   Managhchi, Mohammad Reza ^a   Shokri, Fazel ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TARBIAT MODARES UNIVERSITY   (Iran)

Author keywords

Bethesda assay; ELISA; Factor VIII; Hemophilia A; Inhibitor; Isotype

Indexed keywords

BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 INHIBITOR; EPITOPE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN M; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; BETHESDA ASSAY; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMOPHILIA; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MICROTITER PLATE ASSAY; MOLECULE; OPTICAL DENSITY; PLASMA; PRIORITY JOURNAL; SAMPLE; SCREENING; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; AUTOANTIBODIES; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNOGLOBULIN G; INFANT; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY;

EID: 23844533263     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000086580     Document Type: Article

References (40)

1. Lenting PJ, van Mourik JA, Mertens K: The life cycle of coagulation factor VIII in view of its structure and function. Blood 1998;92:3983-3996.
2. Vehar GA, Keyt B, Eaton D, Rodriguez H, O'Brien DP, Rotblat F, Oppermann H, Keck R, Wood WI, Harkins RN, Tuddenham EGD, Lawn RM, Capon DJ: Structure of human factor VIII. Nature 1984;312:337-342.
3. Pittman DD, Alderman EM, Tomkinson KN, Wang JH, Giles AR, Kaufman RJ: Biochemical, immunological and in vivo functional characterization of B-domain-deleted factor VIII. Blood 1993;81:2925-2935.
4. Pock K, Rizzi A, Josic D: Use of high-resolution techniques for characterization of clotting factor VIII. J Chromatogr A 1999;852:175-188.
5. DiMichele D: Inhibitors: Resolving diagnostic and therapeutic dilemmas. Haemophilia 2002;8:280-287.
6. Lusher JM: First and second generation recombinant factor VIII concentrates in previously untreated patients: Recovery, safety, efficacy and inhibitor development. Semin Thromb Hemost 2002;28:273-276.
7. Cohen AJ, Kessler CM: Acquired inhibitors. Baillièeres Clin Haematol 1996;9:331-354.
8. Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A: Acquired haemophilia: Review and meta-analysis focused on therapy and prognostic factors. Br J Haematol 2003;121:21-35.
9. Scandella DH, Nakai H, Felch M, Mondorf W, Scharrer I, Hoyer LW, Saenko EL: In hemophilia A and autoantibody inhibitor patients: The factor VIII A2 domain and light chain are most immunogenic. Thromb Res 2001;101:377-385.
10. Saint-Remy JM: Immunology of factor VIII inhibitors. Semin Thromb Hemost 2002;28:265-268.
11. Bril WS, Turenhout EA, Kaijen PH, van den Brink EN, Koopman MM, Peters M, Voorberg J: Analysis of factor VIII inhibitors in a haemophilia A patient with an Arg593 → Cys mutation using phage display. Br J Haematol 2002;119:393-396.
12. Reding MT, Okita DK, Diethelm-Okita BM, Anderson TA, Conti-Fine BM: Human CD4+ T-cell epitope repertoire on the C2 domain of coagulation factor VIII. J Thromb Haemost 2003;1:1777-1784.
13. Gilles JG, Arnout J, Vermylen J, Saint-Remy JM: Anti-factor VIII antibodies of hemophilic patients are frequently directed towards non-functional determinants and do not exhibit isotypic restriction. Blood 1993;82:2452-2461.
14. Kasper C, Aledort L, Aronson D, Counts R, Edson JR, van Eys J, Fratantoni J, Green D, Hampton J, Hilgartner M, Levine P, Lazerson J, McMillan C, Penner J, Shapiro S, Shulman NR: A more uniform measurement of FVIII inhibitors. Thromb Diath Haemorrh 1975;34:869-872.
15. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E: The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: Improved specificity and reliability. Thromb Haemost 1995;73:247-251.
16. Peerlinck K, Rosendaal FR, Vermylen J: Incidence of inhibitor development in a group of young hemophilia A patients treated exclusively with lyophilized cryoprecipitate. Blood 1993;81:3332-3335.
17. Klinge J, Auerswald G, Budde U, Klose H, Kreuz W, Lenk H, Scandella D: Detection of all anti-factor VIII antibodies in haemophilia A patients by Bethesda assay and a more sensitive immunoprecipitation assay. Haemophilia 2001;7:26-32.
18. Dazzi F, Vianello TF, Radossi P, Zerbinati P, Carraro P, Polletti A, Girolami A: High incidence of anti-FVIII antibodies against non-coagulant epitopes in haemophilia A patients: A possible role for the half-life of transfused FVIII. Br J Haematol 1996;93:688-693.
19. Gharagozlou S, Ghods R, Bahrami ZS, Roohi A, Jeddi-Tehrani M, Conti-Fine BM, Sharifian RA, Rabbani H, Shokri F: Characterization of human hybridoma clones isolated from hemophilia patients with specificity for different domains of coagulating factor VIII. Hum Antibodies 2003;12:67-76.
20. Spiegel PC Jr, Jacquemin M, Saint-Remy JM, Stoddard BL, Pratt KP: Structure of a factor VIII C2 domain-immunoglobulin G4κ Fab complex: Identification of an inhibitory antibody epitope on the surface of factor VIII. Blood 2001;98:13-19.
21. Jacquemin MG, Desqeuper BG, Benhida A, Vander Elst L, Hoylaerts MF, Bakkus M, Thielemans K, Arnout J, Peerlink K, Gilles JG, Saint-Remy JM: Mechanism and kinetics of factor VIII inactivation: Study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor. Blood 1998;92:496-506.
22. Hoyer LW, Scandella D: Factor VIII inhibitors: Structure and function in autoantibody and hemophilia A patients. Semin Hematol 1994;31:1-5.
23. Gautier PH, Sultan Y, Parquet-Gernez A, Meriane F, Guerois C, Derlon A: Detection and IgG subclass analysis of antibodies to factor VIII in multitransfused haemophiliacs and healthy individuals. Haemophilia 1996;2:88-94.
24. Sanchez-Cuenca JM, Carmona E, Villanueva MJ, Aznar JA: Immunological characterization of factor VIII inhibitors by a sensitive micro-ELISA method. Thromb Res 1990;57:897-908.
25. Lindgren A, Wadenvik H, Tengborn L: Characterization of inhibitors to FVIII with an ELISA in congenital and acquired haemophilia A. Haemophilia 2002;8:644-648.
26. Castaldi PA, Penny R: A macroglobulin with inhibitory activity against coagulation factor VIII. Blood 1970;35:370-376.
27. Fulcher CA, de Graaf Mahoney S, Zimmerman TS: FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting. Blood 1987;69:1475-1480.
28. Fijnvandraat K, Turenhout EAM, van den Brink EN, ten Cate JW, van Mourik JA, Peters M, Voorberg J: The missense mutation Arg 593 → Cys is related to antibody formation in a patient with mild hemophilia A. Blood 1997;89:4371-4377.
29. Lavergne JM, Meyer D, Reisner H: Characterization of human anti-factor VIII antibodies purified by immune complex formation. Blood 1976;48:931-939.
30. Hultin MB, London FS, Shapiro SS, Yount WJ: Heterogeneity of factor VIII antibodies: Further immunochemical and biologic studies. Blood 1977;49:807-817.
31. Shima M, Swamoto Y, Nakai H, Kamisue S, Murakami T, Morichika S, Tanaka I, Hayashi K, Yoshioka A: Measurement of anti-factor VIII IgG, IgG4 and IgM alloantibodies in previously untreated hemophilia A patients treated with recombinant factor VIII. Kogenate Japanese Clinical Study Group. Int J Hematol 1995;62:35-43.
32. Allain JP, Gaillandre A, Lee H: Immunochemical characterization of antibodies to factor VIII in hemophilic and nonhemophilic patients. J Lab Clin Med 1981;97:791-800.
33. Matsumoto T, Shima M, Fukuda K, Nogami K, Giddings JC, Murakami T, Tanaka I, Yoshioka A: Immunological characterization of factor VIII autoantibodies in patients with acquired hemophilia A in the presence or absence of underlying disease. Thromb Res 2001;104:381-388.
34. Blanco AN, Cardozo MA, Candela M, Santarelli MT, Perez Bianco R, Lazzari MA: Anti-factor VIII inhibitors and lupus anticoagulants in haemophilia A patients. Thromb Haemost 1997;77:656-659.
35. Blanco AN, Peirano AA, Grosso SH, Gennari LC, Bianco RP, Lazzari MA: An ELISA system to detect anti-factor VIII antibodies without interference by lupus anticoagulants. Preliminary data in hemophilia A patients. Haematologica 2000;85:1045-1050.
36. Blanco AN, Peirano AA, Grosso SH, Gennari LC, Bianco RP, Lazzari MA: A chromogenic substrate method for detecting and titrating anti-factor VIII antibodies in the presence of lupus anticoagulant. Haematologica 2002;87:271-278.
37. Marlar RA, Griffin JH: Deficiency of protein C inhibitor in combined factor V/VIII deficiency disease. J Clin Invest 1980;66:1186-1189.
38. Di Micco B, Caen J, Colonna G, Macalello MA, Marchese M, Stiuso P, Di Micco P, Morelli F, Metafora S: Inhibition of antithrombin by protein SV-IV normalizes the coagulation of hemophilic blood. Eur J Pharmacol 2000;391:1-9.
39. Koedam JA, Meijers JC, Sixma JJ, Bouma BN: Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor. J Clin Invest 1988;82:1236-1243.
40. Shetty S, Ghosh K, Mohanty D: An ELISA assay for the detection of factor VIII antibodies - comparison with the conventional Bethesda assay in a large cohort of haemophilia samples. Acta Haematol 2003;109:18-22.